Heart Outcomes Prevention Evaluation
HOPE-3 is a large, simple trial evaluating the effects of lipid modification and blood pressure lowering and their combination in a wide range of middle aged people, who are at average risk for vascular events. A total of 12,705 participants were recruited in 21 countries and will be followed for the occurrence of major vascular events over an average of 5 years. HOPE-3 is expected to identify safe and effective cardiovascular prevention strategies which could substantially reduce the risk of CVD in large proportions of the adult population worldwide.
Study Design: Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study.
Intervention: Rosuvastatin, Candesartan/Hydrochlorothiazide, Factorial vs. placebo.
Length of Study: 7 years
# of Patients: 12,705
Patient Populations: Cardiovascular Disease, Stroke, Asymptomatic individuals at moderate risk for CV events.
Available upon study completion.
Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)
| Not available at this time.